Press release
Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics
Lupus Nephritis Clinical Trials
DelveInsight reports that the Lupus Nephritis pipeline involves over 35 key companies actively developing more than 40 investigational therapies.
Lupus Nephritis Overview:
Lupus Nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disorder that disrupts immune tolerance, causing systemic autoimmunity and damage to multiple organs.
SLE affects roughly 7.4-159.4 individuals per 100,000, with a prevalence ranging from 1.4% to 21.9%. LN, a form of glomerulonephritis, leads to inflammation and scarring of the kidney's filtering units (glomeruli) and, in some cases, the entire kidney. The condition is categorized into six histological classes, reflecting different severity levels. The most severe type, proliferative nephritis, results in kidney scarring and impaired function, which can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD), where the kidneys lose their ability to function completely.
Request for a detailed insights report on Lupus Nephritis pipeline insights [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Lupus Nephritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.
Key Takeaways from the Lupus Nephritis Pipeline Report
*
DelveInsight's Lupus Nephritis (LN) pipeline report highlights a dynamic landscape, with over 35 companies actively developing more than 40 investigational therapies for LN treatment.
*
Key players in this space include Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others, all working to advance new treatment options for LN. Promising pipeline candidates in various stages of development include Obinutuzumab, ADX-097, NKX019, and additional therapies.
*
In February 2024, the FDA granted Fast Track designation to AlloNK, an experimental natural killer (NK) cell therapy from Artiva Biotherapeutics, for use in combination with rituximab or obinutuzumab in lupus nephritis. This status is intended to accelerate development and review, enabling earlier patient access. AlloNK is designed to boost antibody-dependent cellular cytotoxicity (ADCC), potentially enhancing the effectiveness of existing antibody-based therapies.
Lupus Nephritis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Lupus Nephritis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lupus Nephritis market.
Download our free sample page report on Lupus Nephritis pipeline insights [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lupus Nephritis Emerging Drugs
*
Obinutuzumab: Hoffmann-La Roche
*
ADX-097: Q32 Bio
*
NKX019: Nkarta
Lupus Nephritis Companies
Over 35 leading companies are actively working on therapies for Lupus Nephritis, with Hoffmann-La Roche having a candidate in the most advanced stage, currently in Phase III clinical trials.
DelveInsight's report covers around 40+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Lupus Nephritis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Lupus Nephritis Therapies and Key Companies: Lupus Nephritis Clinical Trials and advancements [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lupus Nephritis Pipeline Therapeutic Assessment
- Lupus Nephritis Assessment by Product Type
- Lupus Nephritis By Stage
- Lupus Nephritis Assessment by Route of Administration
- Lupus Nephritis Assessment by Molecule Type
Download Lupus Nephritis Sample report to know in detail about the Lupus Nephritis treatment market @ Lupus Nephritis Therapeutic Assessment [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Lupus Nephritis Current Treatment Patterns
4. Lupus Nephritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lupus Nephritis Late-Stage Products (Phase-III)
7. Lupus Nephritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lupus Nephritis Discontinued Products
13. Lupus Nephritis Product Profiles
14. Lupus Nephritis Key Companies
15. Lupus Nephritis Key Products
16. Dormant and Discontinued Products
17. Lupus Nephritis Unmet Needs
18. Lupus Nephritis Future Perspectives
19. Lupus Nephritis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Lupus Nephritis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-clinical-trials-companies-therapies-treatment-pipeline-hoffmannla-roche-qilu-pharmaceutical-vera-therapeutics-kyverna-therapeutics-cabaletta-bio-takeda-nkarta-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics here
News-ID: 4155056 • Views: …
More Releases from ABNewswire
PCSK9 Inhibitors Market Landscape: Clinical Pipeline, Competitive Strategies, an …
DelveInsight's PCSK9 Inhibitors Market Report highlights strong growth potential, with the 7MM market projected to expand significantly by 2034 from USD 2B in 2023. The U.S. leads with ~USD 900M. Key players include Sanofi, Regeneron, Amgen, AstraZeneca, LIB Therapeutics, Merck, Novartis, Alnylam, Aqur Biosciences, and CiVi Biopharma. Current leaders PRALUENT and REPATHA dominate, while pipeline assets like LIB003 and MK-0616 signal the next wave of innovation.
DelveInsight's comprehensive [https://www.delveinsight.com/report-store/pcsk9-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report, provides…
Bronchiectasis Treatment Landscape: FDA Approves BRINSUPRI, First Disease-Modify …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of BRINSUPRI (brensocatib) by Insmed Incorporated (NASDAQ: INSM). This landmark approval marks the first disease-specific therapy for bronchiectasis, offering new hope for over one million patients suffering from this chronic, progressive lung disease characterized by irreversible bronchial airway dilation and impaired mucociliary function.
Key Bronchiectasis Market Highlights
*
BRINSUPRI's approval is expected to be a key bronchiectasis market driver,…
Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba) by Precigen, Inc. (NASDAQ: PGEN). This landmark approval marks the first FDA-approved therapy for recurrent respiratory papillomatosis in history, offering unprecedented hope for thousands of patients suffering from this rare and debilitating condition caused by human papillomavirus infection.
Key Recurrent Respiratory Papillomatosis Market Highlights
*
PAPZIMEOS approval represents a paradigm shift in the recurrent respiratory…
Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Y …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of TONMYA (cyclobenzaprine HCl sublingual tablets) by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). This landmark approval marks the first new fibromyalgia treatment approved by the FDA in more than 15 years, offering new hope for millions of patients suffering from this debilitating chronic pain condition.
Key Fibromyalgia Market Highlights
*
TONMYA's approval is expected to be a key driver…
More Releases for Lupus
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Primary Catalyst Driving Lupus Therapeutics Market Evolution in 2025: Rising Res …
"What Is the Future Outlook for the Lupus Therapeutics Market's Size and Growth Rate?
The market size for lupus therapeutics has seen substantial growth in the past few years. It is projected to expand from $2.74 billion in 2024 to $2.99 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. The historic growth of this market can be associated with a rise in cases of lupus, increased funding…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
